BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
2 Piermatteo L, Scutari R, Chirichiello R, Alkhatib M, Malagnino V, Bertoli A, Iapadre N, Ciotti M, Sarmati L, Andreoni M, Ceccherini-Silberstein F, Salpini R, Svicher V. Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. Methods 2021:S1046-2023(21)00137-7. [PMID: 34000391 DOI: 10.1016/j.ymeth.2021.05.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Panevkina S, Ibragimov E, Abdurakhmanov D. High Rate of Virologic Response After Discontinuation of Nucleos(T)Ide Analogues in Caucasian Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00101-4. [PMID: 33548510 DOI: 10.1016/j.cgh.2021.01.050] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Peña-Asensio J, Calvo H, Miquel J, Sanz-de-Villalobos E, González-Praetorius A, Torralba M, Larrubia JR. Model to predict on-treatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2022;55:1545-59. [PMID: 35224746 DOI: 10.1111/apt.16850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Huang D, Yan W, Han M, Yuan W, Wang P, Chen Y, Wan X, Luo X, Wu D, Ning Q. Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg-IFN-ɑ. Antiviral Res 2021;197:105220. [PMID: 34848218 DOI: 10.1016/j.antiviral.2021.105220] [Reference Citation Analysis]
6 Chang ML, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci 2022;23:1552. [PMID: 35163476 DOI: 10.3390/ijms23031552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vachon A, Osiowy C. Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Viruses 2021;13:951. [PMID: 34064049 DOI: 10.3390/v13060951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ren P, Li H, Huang Y, Jiang J, Guo S, Cao Z, Zhang C, Zhou T, Gan Q, Zhao S, Chen L, Guo Q, Cai W, Wang H, Hu P, Xie Q. A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. Antiviral Res 2021;194:105163. [PMID: 34389410 DOI: 10.1016/j.antiviral.2021.105163] [Reference Citation Analysis]
9 Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. Hepatol Commun 2021. [PMID: 34894108 DOI: 10.1002/hep4.1875] [Reference Citation Analysis]
10 Tout I, Loureiro D, Asselah T. The Changing Demographics of Hepatitis B Virus Infection. Clin Liver Dis 2021;25:673-87. [PMID: 34593147 DOI: 10.1016/j.cld.2021.06.001] [Reference Citation Analysis]